Periodic Reporting for period 1 - BloodStemPLUS (Commercial feasibility study of a technology that multiplies blood stem cells to increase the success of transplants for cancer treatment)

GrowingFormula Lda (trading as StemCell2MAX) has investigated the marketing and commercial feasibility of the clinical application of their proprietary mix of neurotrophic factors. The value proposition of StemCell2MAX's technology relies on the ability to expand hematopoietic...